Amylyx Pharmaceuticals, Inc. Depreciation
Amylyx Pharmaceuticals, Inc. (AMLX) reported Depreciation of $141.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. depreciation for the quarter ending 2026-06-30 was $43.00K, a 69.50% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. depreciation for the quarter ending 2026-03-31 was $98.00K, a 37.18% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. depreciation for the quarter ending 2025-12-31 was $108.00K, a 32.50% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. depreciation for the quarter ending 2025-09-30 was $120.00K, a 45.70% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. depreciation for fiscal 2025 was $525.00K, a 41.92% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. depreciation for fiscal 2024 was $904.00K, a 16.91% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. depreciation for fiscal 2023 was $1.09M, a 123.41% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. depreciation for fiscal 2022 was $487.00K, a 836.54% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $141.00K 10-Q · filed 2026-08-06 | $249.00K derived: sum of 3 quarters · filed 2026-08-06 | $369.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $98.00K 10-Q · filed 2026-05-07 | $206.00K derived: sum of 2 quarters · filed 2026-05-07 | $326.00K derived: sum of 3 quarters · filed 2026-05-07 | $467.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $228.00K derived: sum of 2 quarters · filed 2026-03-03 | $369.00K derived: sum of 3 quarters · filed 2026-08-06 | $525.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $261.00K derived: sum of 2 quarters · filed 2026-08-06 | $417.00K 10-Q · filed 2025-11-06 | $577.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $297.00K 10-Q · filed 2026-08-06 | $457.00K derived: sum of 3 quarters · filed 2026-08-06 | $678.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $156.00K 10-Q · filed 2026-05-07 | $316.00K derived: sum of 2 quarters · filed 2026-05-07 | $537.00K derived: sum of 3 quarters · filed 2026-05-07 | $745.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $381.00K derived: sum of 2 quarters · filed 2026-03-03 | $589.00K derived: sum of 3 quarters · filed 2026-03-03 | $904.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $429.00K derived: sum of 2 quarters · filed 2025-11-06 | $744.00K 10-Q · filed 2025-11-06 | $1.04M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $523.00K 10-Q · filed 2025-08-07 | $824.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.13M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $315.00K 10-Q · filed 2025-05-08 | $616.00K derived: sum of 2 quarters · filed 2025-05-08 | $918.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $301.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $603.00K derived: sum of 2 quarters · filed 2025-03-04 | $884.00K derived: sum of 3 quarters · filed 2025-03-04 | $1.09M 10-K · filed 2025-03-04 |
| 2023-09-30 | $302.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $583.00K derived: sum of 2 quarters · filed 2024-11-07 | $787.00K 10-Q · filed 2024-11-07 | $969.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $485.00K 10-Q · filed 2024-08-08 | $667.00K derived: sum of 3 quarters · filed 2024-08-08 | $832.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $204.00K 10-Q · filed 2024-05-09 | $386.00K derived: sum of 2 quarters · filed 2024-05-09 | $551.00K derived: sum of 3 quarters · filed 2024-05-09 | $656.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $347.00K derived: sum of 2 quarters · filed 2024-02-22 | $452.00K derived: sum of 3 quarters · filed 2024-02-22 | $487.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $270.00K derived: sum of 2 quarters · filed 2023-11-09 | $305.00K 10-Q · filed 2023-11-09 | $327.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $140.00K 10-Q · filed 2023-08-10 | $162.00K derived: sum of 3 quarters · filed 2024-02-22 | $172.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $35.00K 10-Q · filed 2023-05-11 | $57.00K derived: sum of 2 quarters · filed 2024-02-22 | $67.00K derived: sum of 3 quarters · filed 2024-02-22 | $77.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $32.00K derived: sum of 2 quarters · filed 2024-02-22 | $42.00K derived: sum of 3 quarters · filed 2024-02-22 | $52.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $20.00K derived: sum of 2 quarters · filed 2022-11-10 | $30.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $20.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |